Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Up 33.5% in March

Tenax Therapeutics, Inc. (NASDAQ:TENX) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 49,000 shares, an increase of 33.5% from the March 15th total of 36,700 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average trading volume of 340,200 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Tenax Therapeutics

An institutional investor recently bought a new position in Tenax Therapeutics stock. Vanguard Group Inc. bought a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 186,046 shares of the specialty pharmaceutical company’s stock, valued at approximately $51,000. Vanguard Group Inc. owned 62.02% of Tenax Therapeutics as of its most recent filing with the Securities and Exchange Commission. 1.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on TENX shares. Roth Mkm reissued a “buy” rating on shares of Tenax Therapeutics in a research note on Tuesday, February 20th. StockNews.com assumed coverage on Tenax Therapeutics in a research note on Wednesday, January 10th. They issued a “sell” rating for the company.

Tenax Therapeutics Price Performance

Shares of NASDAQ:TENX opened at $3.76 on Monday. Tenax Therapeutics has a 1-year low of $3.48 and a 1-year high of $61.20. The business has a 50-day moving average price of $4.55 and a two-hundred day moving average price of $15.22.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.